Akoya Biosciences Stock Analysis
AKYA Stock | USD 1.70 0.02 1.19% |
Akoya Biosciences is undervalued with Real Value of 2.15 and Target Price of 3.5. The main objective of Akoya Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Akoya Biosciences is worth, separate from its market price. There are two main types of Akoya Biosciences' stock analysis: fundamental analysis and technical analysis.
The Akoya Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Akoya Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Akoya |
Akoya Stock Analysis Notes
About 67.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.12. Akoya Biosciences had not issued any dividends in recent years. Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Akoya Biosciences operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 319 people. For more info on Akoya Biosciences please contact Brian McKelligon at 855 896 8401 or go to https://www.akoyabio.com.Akoya Biosciences Quarterly Total Revenue |
|
Akoya Biosciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Akoya Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Akoya Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Akoya Biosciences generated a negative expected return over the last 90 days | |
Akoya Biosciences may become a speculative penny stock | |
Akoya Biosciences has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 81.67 M. Net Loss for the year was (55.37 M) with profit before overhead, payroll, taxes, and interest of 47.88 M. | |
Akoya Biosciences currently holds about 87.61 M in cash with (44.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Akoya Biosciences has a poor financial position based on the latest SEC disclosures | |
Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Akoya Q4 Earnings Snapshot |
Akoya Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akoya Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of March 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Akoya Largest EPS Surprises
Earnings surprises can significantly impact Akoya Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.2 | -0.1786 | 0.0214 | 10 | ||
2021-08-10 | 2021-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2024-03-04 | 2023-12-31 | -0.27 | -0.22 | 0.05 | 18 |
Akoya Stock Institutional Investors
Shares | Osterweis Capital Management Inc | 2024-12-31 | 126.1 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 122 K | Bridgeway Capital Management, Llc | 2024-12-31 | 105.6 K | Ubs Group Ag | 2024-12-31 | 85.2 K | Goldman Sachs Group Inc | 2024-12-31 | 80.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 63 K | Deutsche Bank Ag | 2024-12-31 | 54.8 K | Bank Of New York Mellon Corp | 2024-12-31 | 50.7 K | Citigroup Inc | 2024-12-31 | 48.8 K | Blue Water Life Science Advisors, Llc | 2024-12-31 | 4.7 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Akoya Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 84.69 M.Akoya Profitablity
The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.60) | (0.63) | |
Return On Capital Employed | (0.49) | (0.51) | |
Return On Assets | (0.44) | (0.47) | |
Return On Equity | (7.29) | (6.93) |
Management Efficiency
Akoya Biosciences has return on total asset (ROA) of (0.1686) % which means that it has lost $0.1686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8045) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.63. In addition to that, Return On Capital Employed is expected to decline to -0.51. At present, Akoya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 24.5 M, whereas Other Assets are forecasted to decline to 0.86.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.15 | 0.15 | |
Tangible Book Value Per Share | (0.51) | (0.48) | |
Enterprise Value Over EBITDA | (2.94) | (3.09) | |
Price Book Value Ratio | 14.90 | 15.65 | |
Enterprise Value Multiple | (2.94) | (3.09) | |
Price Fair Value | 14.90 | 15.65 | |
Enterprise Value | 109.4 M | 103.9 M |
The strategic vision of Akoya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Technical Drivers
As of the 23rd of March, Akoya Biosciences shows the Risk Adjusted Performance of (0.06), mean deviation of 3.63, and Standard Deviation of 4.61. Akoya Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Akoya Biosciences Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Akoya Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Akoya Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Akoya Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akoya Biosciences Outstanding Bonds
Akoya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akoya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akoya bonds can be classified according to their maturity, which is the date when Akoya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Akoya Biosciences Predictive Daily Indicators
Akoya Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Akoya Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Akoya Biosciences Forecast Models
Akoya Biosciences' time-series forecasting models are one of many Akoya Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Akoya Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Akoya Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Akoya Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Akoya shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Akoya Biosciences. By using and applying Akoya Stock analysis, traders can create a robust methodology for identifying Akoya entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.68) | (0.71) | |
Operating Profit Margin | (0.57) | (0.60) | |
Net Loss | (0.68) | (0.71) | |
Gross Profit Margin | 0.59 | 0.65 |
Current Akoya Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Akoya analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Akoya analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
3.5 | Buy | 8 | Odds |
Most Akoya analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Akoya stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Akoya Biosciences, talking to its executives and customers, or listening to Akoya conference calls.
Akoya Stock Analysis Indicators
Akoya Biosciences stock analysis indicators help investors evaluate how Akoya Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Akoya Biosciences shares will generate the highest return on investment. By understating and applying Akoya Biosciences stock analysis, traders can identify Akoya Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 83.8 M | |
Long Term Debt | 76.2 M | |
Common Stock Shares Outstanding | 49.4 M | |
Total Stockholder Equity | 7.6 M | |
Tax Provision | 146 K | |
Property Plant And Equipment Net | 13 M | |
Cash And Short Term Investments | 35 M | |
Cash | 11.8 M | |
Accounts Payable | 8.8 M | |
Net Debt | -3.8 M | |
50 Day M A | 2.249 | |
Total Current Liabilities | 29.4 M | |
Other Operating Expenses | 128.4 M | |
Non Current Assets Total | 48.3 M | |
Non Currrent Assets Other | 2.5 M | |
Stock Based Compensation | 9.3 M |
Complementary Tools for Akoya Stock analysis
When running Akoya Biosciences' price analysis, check to measure Akoya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akoya Biosciences is operating at the current time. Most of Akoya Biosciences' value examination focuses on studying past and present price action to predict the probability of Akoya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akoya Biosciences' price. Additionally, you may evaluate how the addition of Akoya Biosciences to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |